Urogen Pharma (NASDAQ:URGN) Earns Buy Rating from HC Wainwright

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $45.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 56.36% from the company’s previous close.

Other research analysts also recently issued reports about the stock. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. Oppenheimer boosted their price objective on shares of Urogen Pharma from $34.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. D. Boral Capital reissued a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a research report on Tuesday, March 31st. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.67.

Urogen Pharma Price Performance

NASDAQ URGN opened at $28.78 on Monday. The stock has a market capitalization of $1.40 billion, a PE ratio of -10.47 and a beta of 1.58. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $32.37. The business’s 50-day moving average is $21.76 and its 200 day moving average is $22.06.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.01. The business had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. As a group, equities research analysts anticipate that Urogen Pharma will post -0.98 earnings per share for the current year.

Institutional Trading of Urogen Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of URGN. Osaic Holdings Inc. grew its position in shares of Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Urogen Pharma by 27.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after buying an additional 486 shares during the period. State of Wyoming purchased a new stake in shares of Urogen Pharma in the 3rd quarter worth about $66,000. Russell Investments Group Ltd. grew its position in shares of Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after buying an additional 3,125 shares during the period. Finally, Strs Ohio purchased a new stake in shares of Urogen Pharma in the 3rd quarter worth about $76,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.